Last reviewed · How we verify
NCT02844491: Epitopes-LNH01
Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B
trial testing additional biological samples in Hematological Malignancies B in 28 participants. Terminated before completion.
19 September 2014
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 28 |
| Start date | 22 January 2013 |
| Primary completion | 19 September 2014 |
| Estimated completion | 19 September 2014 |
| Sites | 1 location across France |
Drugs / interventions tested
- additional biological samples
Conditions studied
- Hematological Malignancies B — all drugs for Hematological Malignancies B →
Sponsor
Centre Hospitalier Universitaire de Besancon
Who can join
Adults 18 to 70, any sex, with Hematological Malignancies B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform. The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides. If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.
Kye Y, Nagineni L, Gadad S, Ramirez F, et al · · 2022 · cited 7× · PMID 36077792 · DOI 10.3390/cancers14174255 -
Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.
Zhu ZM, Wu XM, Hu Y, Bian XL, et al · · 2025 · cited 1× · PMID 41399527 · DOI 10.1002/mco2.70545
Verify or expand the search:
- PubMed search for NCT02844491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire de Besancon trials
Trials by the same sponsor.
- NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
- NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
- NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02844491 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
- Last refreshed: 2 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02844491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing